nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—SLC22A6—Pravastatin—atherosclerosis	0.094	0.128	CbGbCtD
Methazolamide—CYP2C19—Rosuvastatin—atherosclerosis	0.0571	0.0776	CbGbCtD
Methazolamide—CYP2C19—Simvastatin—atherosclerosis	0.0531	0.0722	CbGbCtD
Methazolamide—CYP2C19—Lovastatin—atherosclerosis	0.0519	0.0706	CbGbCtD
Methazolamide—CYP2D6—Niacin—atherosclerosis	0.051	0.0694	CbGbCtD
Methazolamide—CYP2C9—Rosuvastatin—atherosclerosis	0.0475	0.0645	CbGbCtD
Methazolamide—CYP2C9—Simvastatin—atherosclerosis	0.0441	0.06	CbGbCtD
Methazolamide—CYP2C9—Pravastatin—atherosclerosis	0.0432	0.0587	CbGbCtD
Methazolamide—CYP2C9—Lovastatin—atherosclerosis	0.0432	0.0587	CbGbCtD
Methazolamide—CYP2D6—Simvastatin—atherosclerosis	0.0403	0.0549	CbGbCtD
Methazolamide—CYP2D6—Lovastatin—atherosclerosis	0.0395	0.0537	CbGbCtD
Methazolamide—CYP2D6—Pravastatin—atherosclerosis	0.0395	0.0537	CbGbCtD
Methazolamide—CYP3A4—Ezetimibe—atherosclerosis	0.0276	0.0375	CbGbCtD
Methazolamide—CYP3A4—Rosuvastatin—atherosclerosis	0.0276	0.0375	CbGbCtD
Methazolamide—CYP3A4—Simvastatin—atherosclerosis	0.0257	0.0349	CbGbCtD
Methazolamide—CYP3A4—Pravastatin—atherosclerosis	0.0251	0.0341	CbGbCtD
Methazolamide—CYP3A4—Lovastatin—atherosclerosis	0.0251	0.0341	CbGbCtD
Methazolamide—Hepatic necrosis—Lovastatin—atherosclerosis	0.00532	0.0283	CcSEcCtD
Methazolamide—Hepatic necrosis—Simvastatin—atherosclerosis	0.00497	0.0265	CcSEcCtD
Methazolamide—Hepatic necrosis—Pravastatin—atherosclerosis	0.00449	0.0239	CcSEcCtD
Methazolamide—Blood disorder—Rosuvastatin—atherosclerosis	0.00436	0.0232	CcSEcCtD
Methazolamide—Tingling sensation—Niacin—atherosclerosis	0.0033	0.0176	CcSEcCtD
Methazolamide—Hepatic failure—Rosuvastatin—atherosclerosis	0.00294	0.0157	CcSEcCtD
Methazolamide—Photosensitivity—Lovastatin—atherosclerosis	0.00255	0.0136	CcSEcCtD
Methazolamide—Photosensitivity—Ezetimibe—atherosclerosis	0.0025	0.0133	CcSEcCtD
Methazolamide—Hepatic failure—Lovastatin—atherosclerosis	0.0025	0.0133	CcSEcCtD
Methazolamide—Haemolytic anaemia—Lovastatin—atherosclerosis	0.00248	0.0132	CcSEcCtD
Methazolamide—Hepatic failure—Ezetimibe—atherosclerosis	0.00245	0.013	CcSEcCtD
Methazolamide—Urine output increased—Niacin—atherosclerosis	0.0024	0.0128	CcSEcCtD
Methazolamide—Photosensitivity—Simvastatin—atherosclerosis	0.00239	0.0127	CcSEcCtD
Methazolamide—Hepatic failure—Simvastatin—atherosclerosis	0.00233	0.0124	CcSEcCtD
Methazolamide—Haemolytic anaemia—Simvastatin—atherosclerosis	0.00232	0.0124	CcSEcCtD
Methazolamide—Polyuria—Niacin—atherosclerosis	0.00219	0.0117	CcSEcCtD
Methazolamide—Photosensitivity—Pravastatin—atherosclerosis	0.00216	0.0115	CcSEcCtD
Methazolamide—Hepatic failure—Pravastatin—atherosclerosis	0.00211	0.0112	CcSEcCtD
Methazolamide—Haemolytic anaemia—Pravastatin—atherosclerosis	0.0021	0.0112	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Lovastatin—atherosclerosis	0.00202	0.0107	CcSEcCtD
Methazolamide—Haematuria—Rosuvastatin—atherosclerosis	0.00194	0.0103	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.00189	0.0101	CcSEcCtD
Methazolamide—Photosensitivity reaction—Lovastatin—atherosclerosis	0.00177	0.00942	CcSEcCtD
Methazolamide—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.00174	0.00923	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.00171	0.00912	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.00171	0.00909	CcSEcCtD
Methazolamide—Photosensitivity reaction—Simvastatin—atherosclerosis	0.00165	0.00881	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.0016	0.00853	CcSEcCtD
Methazolamide—Photosensitivity reaction—Pravastatin—atherosclerosis	0.0015	0.00796	CcSEcCtD
Methazolamide—Erythema multiforme—Lovastatin—atherosclerosis	0.00147	0.00781	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.00145	0.00771	CcSEcCtD
Methazolamide—Erythema multiforme—Ezetimibe—atherosclerosis	0.00144	0.00766	CcSEcCtD
Methazolamide—Erythema multiforme—Simvastatin—atherosclerosis	0.00137	0.0073	CcSEcCtD
Methazolamide—Dysgeusia—Lovastatin—atherosclerosis	0.00132	0.00704	CcSEcCtD
Methazolamide—Confusional state—Rosuvastatin—atherosclerosis	0.00131	0.00698	CcSEcCtD
Methazolamide—Ill-defined disorder—Lovastatin—atherosclerosis	0.00125	0.00667	CcSEcCtD
Methazolamide—Tinnitus—Niacin—atherosclerosis	0.00124	0.00661	CcSEcCtD
Methazolamide—Erythema multiforme—Pravastatin—atherosclerosis	0.00124	0.0066	CcSEcCtD
Methazolamide—Dysgeusia—Simvastatin—atherosclerosis	0.00124	0.00658	CcSEcCtD
Methazolamide—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00123	0.00654	CcSEcCtD
Methazolamide—Tinnitus—Pravastatin—atherosclerosis	0.00122	0.00651	CcSEcCtD
Methazolamide—Malaise—Lovastatin—atherosclerosis	0.00122	0.00648	CcSEcCtD
Methazolamide—Vertigo—Lovastatin—atherosclerosis	0.00121	0.00646	CcSEcCtD
Methazolamide—Leukopenia—Lovastatin—atherosclerosis	0.00121	0.00643	CcSEcCtD
Methazolamide—Malaise—Ezetimibe—atherosclerosis	0.00119	0.00636	CcSEcCtD
Methazolamide—Ill-defined disorder—Simvastatin—atherosclerosis	0.00117	0.00624	CcSEcCtD
Methazolamide—Paraesthesia—Rosuvastatin—atherosclerosis	0.00117	0.00622	CcSEcCtD
Methazolamide—Dyspepsia—Rosuvastatin—atherosclerosis	0.00114	0.00609	CcSEcCtD
Methazolamide—Malaise—Simvastatin—atherosclerosis	0.00114	0.00606	CcSEcCtD
Methazolamide—Discomfort—Lovastatin—atherosclerosis	0.00114	0.00605	CcSEcCtD
Methazolamide—Vertigo—Simvastatin—atherosclerosis	0.00113	0.00604	CcSEcCtD
Methazolamide—Leukopenia—Simvastatin—atherosclerosis	0.00113	0.00602	CcSEcCtD
Methazolamide—Dysgeusia—Pravastatin—atherosclerosis	0.00112	0.00595	CcSEcCtD
Methazolamide—Discomfort—Ezetimibe—atherosclerosis	0.00111	0.00593	CcSEcCtD
Methazolamide—Confusional state—Lovastatin—atherosclerosis	0.00111	0.00591	CcSEcCtD
Methazolamide—Anaphylactic shock—Lovastatin—atherosclerosis	0.0011	0.00587	CcSEcCtD
Methazolamide—Confusional state—Ezetimibe—atherosclerosis	0.00109	0.0058	CcSEcCtD
Methazolamide—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00108	0.00575	CcSEcCtD
Methazolamide—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00107	0.0057	CcSEcCtD
Methazolamide—Discomfort—Simvastatin—atherosclerosis	0.00106	0.00565	CcSEcCtD
Methazolamide—Ill-defined disorder—Pravastatin—atherosclerosis	0.00106	0.00564	CcSEcCtD
Methazolamide—Anorexia—Lovastatin—atherosclerosis	0.00105	0.00559	CcSEcCtD
Methazolamide—Vertigo—Niacin—atherosclerosis	0.00104	0.00555	CcSEcCtD
Methazolamide—Confusional state—Simvastatin—atherosclerosis	0.00104	0.00553	CcSEcCtD
Methazolamide—Leukopenia—Niacin—atherosclerosis	0.00104	0.00553	CcSEcCtD
Methazolamide—Urticaria—Rosuvastatin—atherosclerosis	0.00103	0.0055	CcSEcCtD
Methazolamide—Anaphylactic shock—Simvastatin—atherosclerosis	0.00103	0.00549	CcSEcCtD
Methazolamide—Malaise—Pravastatin—atherosclerosis	0.00103	0.00548	CcSEcCtD
Methazolamide—Vertigo—Pravastatin—atherosclerosis	0.00103	0.00546	CcSEcCtD
Methazolamide—Leukopenia—Pravastatin—atherosclerosis	0.00102	0.00544	CcSEcCtD
Methazolamide—Paraesthesia—Lovastatin—atherosclerosis	0.00099	0.00527	CcSEcCtD
Methazolamide—Anorexia—Simvastatin—atherosclerosis	0.000983	0.00523	CcSEcCtD
Methazolamide—Paraesthesia—Ezetimibe—atherosclerosis	0.000971	0.00517	CcSEcCtD
Methazolamide—Dyspepsia—Lovastatin—atherosclerosis	0.00097	0.00516	CcSEcCtD
Methazolamide—Discomfort—Pravastatin—atherosclerosis	0.000961	0.00511	CcSEcCtD
Methazolamide—Decreased appetite—Lovastatin—atherosclerosis	0.000958	0.0051	CcSEcCtD
Methazolamide—Dyspepsia—Ezetimibe—atherosclerosis	0.000952	0.00506	CcSEcCtD
Methazolamide—Fatigue—Lovastatin—atherosclerosis	0.00095	0.00506	CcSEcCtD
Methazolamide—Anaphylactic shock—Niacin—atherosclerosis	0.000947	0.00504	CcSEcCtD
Methazolamide—Confusional state—Pravastatin—atherosclerosis	0.00094	0.005	CcSEcCtD
Methazolamide—Decreased appetite—Ezetimibe—atherosclerosis	0.00094	0.005	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000933	0.00497	CcSEcCtD
Methazolamide—Asthenia—Rosuvastatin—atherosclerosis	0.000933	0.00497	CcSEcCtD
Methazolamide—Anaphylactic shock—Pravastatin—atherosclerosis	0.000932	0.00496	CcSEcCtD
Methazolamide—Fatigue—Ezetimibe—atherosclerosis	0.000932	0.00496	CcSEcCtD
Methazolamide—Paraesthesia—Simvastatin—atherosclerosis	0.000926	0.00493	CcSEcCtD
Methazolamide—Feeling abnormal—Lovastatin—atherosclerosis	0.000908	0.00483	CcSEcCtD
Methazolamide—Dyspepsia—Simvastatin—atherosclerosis	0.000907	0.00483	CcSEcCtD
Methazolamide—Anorexia—Niacin—atherosclerosis	0.000902	0.0048	CcSEcCtD
Methazolamide—Decreased appetite—Simvastatin—atherosclerosis	0.000896	0.00477	CcSEcCtD
Methazolamide—Feeling abnormal—Ezetimibe—atherosclerosis	0.000891	0.00474	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00089	0.00474	CcSEcCtD
Methazolamide—Diarrhoea—Rosuvastatin—atherosclerosis	0.00089	0.00474	CcSEcCtD
Methazolamide—Fatigue—Simvastatin—atherosclerosis	0.000889	0.00473	CcSEcCtD
Methazolamide—Anorexia—Pravastatin—atherosclerosis	0.000888	0.00473	CcSEcCtD
Methazolamide—Urticaria—Lovastatin—atherosclerosis	0.000876	0.00466	CcSEcCtD
Methazolamide—Body temperature increased—Lovastatin—atherosclerosis	0.000871	0.00464	CcSEcCtD
Methazolamide—Urticaria—Ezetimibe—atherosclerosis	0.000859	0.00457	CcSEcCtD
Methazolamide—Body temperature increased—Ezetimibe—atherosclerosis	0.000855	0.00455	CcSEcCtD
Methazolamide—Paraesthesia—Niacin—atherosclerosis	0.00085	0.00452	CcSEcCtD
Methazolamide—Feeling abnormal—Simvastatin—atherosclerosis	0.00085	0.00452	CcSEcCtD
Methazolamide—Somnolence—Niacin—atherosclerosis	0.000842	0.00448	CcSEcCtD
Methazolamide—Paraesthesia—Pravastatin—atherosclerosis	0.000837	0.00445	CcSEcCtD
Methazolamide—Dyspepsia—Niacin—atherosclerosis	0.000833	0.00443	CcSEcCtD
Methazolamide—Decreased appetite—Niacin—atherosclerosis	0.000823	0.00438	CcSEcCtD
Methazolamide—Dyspepsia—Pravastatin—atherosclerosis	0.00082	0.00437	CcSEcCtD
Methazolamide—Rash—Rosuvastatin—atherosclerosis	0.00082	0.00436	CcSEcCtD
Methazolamide—Dermatitis—Rosuvastatin—atherosclerosis	0.000819	0.00436	CcSEcCtD
Methazolamide—Urticaria—Simvastatin—atherosclerosis	0.000819	0.00436	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Niacin—atherosclerosis	0.000817	0.00435	CcSEcCtD
Methazolamide—Body temperature increased—Simvastatin—atherosclerosis	0.000815	0.00434	CcSEcCtD
Methazolamide—Headache—Rosuvastatin—atherosclerosis	0.000815	0.00434	CcSEcCtD
Methazolamide—Decreased appetite—Pravastatin—atherosclerosis	0.00081	0.00431	CcSEcCtD
Methazolamide—Fatigue—Pravastatin—atherosclerosis	0.000804	0.00428	CcSEcCtD
Methazolamide—Asthenia—Lovastatin—atherosclerosis	0.000791	0.00421	CcSEcCtD
Methazolamide—Asthenia—Ezetimibe—atherosclerosis	0.000776	0.00413	CcSEcCtD
Methazolamide—Nausea—Rosuvastatin—atherosclerosis	0.000772	0.00411	CcSEcCtD
Methazolamide—Feeling abnormal—Pravastatin—atherosclerosis	0.000768	0.00409	CcSEcCtD
Methazolamide—Diarrhoea—Lovastatin—atherosclerosis	0.000754	0.00401	CcSEcCtD
Methazolamide—Urticaria—Niacin—atherosclerosis	0.000752	0.004	CcSEcCtD
Methazolamide—Body temperature increased—Niacin—atherosclerosis	0.000748	0.00398	CcSEcCtD
Methazolamide—Urticaria—Pravastatin—atherosclerosis	0.00074	0.00394	CcSEcCtD
Methazolamide—Asthenia—Simvastatin—atherosclerosis	0.00074	0.00394	CcSEcCtD
Methazolamide—Diarrhoea—Ezetimibe—atherosclerosis	0.00074	0.00394	CcSEcCtD
Methazolamide—Body temperature increased—Pravastatin—atherosclerosis	0.000737	0.00392	CcSEcCtD
Methazolamide—Diarrhoea—Simvastatin—atherosclerosis	0.000705	0.00375	CcSEcCtD
Methazolamide—Vomiting—Lovastatin—atherosclerosis	0.000701	0.00373	CcSEcCtD
Methazolamide—Rash—Lovastatin—atherosclerosis	0.000695	0.0037	CcSEcCtD
Methazolamide—Dermatitis—Lovastatin—atherosclerosis	0.000694	0.0037	CcSEcCtD
Methazolamide—Headache—Lovastatin—atherosclerosis	0.00069	0.00367	CcSEcCtD
Methazolamide—Vomiting—Ezetimibe—atherosclerosis	0.000687	0.00366	CcSEcCtD
Methazolamide—Rash—Ezetimibe—atherosclerosis	0.000682	0.00363	CcSEcCtD
Methazolamide—Dermatitis—Ezetimibe—atherosclerosis	0.000681	0.00362	CcSEcCtD
Methazolamide—Asthenia—Niacin—atherosclerosis	0.000679	0.00361	CcSEcCtD
Methazolamide—Headache—Ezetimibe—atherosclerosis	0.000677	0.0036	CcSEcCtD
Methazolamide—Asthenia—Pravastatin—atherosclerosis	0.000669	0.00356	CcSEcCtD
Methazolamide—Vomiting—Simvastatin—atherosclerosis	0.000655	0.00349	CcSEcCtD
Methazolamide—Nausea—Lovastatin—atherosclerosis	0.000655	0.00348	CcSEcCtD
Methazolamide—Rash—Simvastatin—atherosclerosis	0.00065	0.00346	CcSEcCtD
Methazolamide—Dermatitis—Simvastatin—atherosclerosis	0.000649	0.00346	CcSEcCtD
Methazolamide—Diarrhoea—Niacin—atherosclerosis	0.000648	0.00345	CcSEcCtD
Methazolamide—Headache—Simvastatin—atherosclerosis	0.000646	0.00344	CcSEcCtD
Methazolamide—Nausea—Ezetimibe—atherosclerosis	0.000642	0.00342	CcSEcCtD
Methazolamide—Diarrhoea—Pravastatin—atherosclerosis	0.000638	0.00339	CcSEcCtD
Methazolamide—Nausea—Simvastatin—atherosclerosis	0.000612	0.00326	CcSEcCtD
Methazolamide—Vomiting—Niacin—atherosclerosis	0.000602	0.0032	CcSEcCtD
Methazolamide—Rash—Niacin—atherosclerosis	0.000597	0.00318	CcSEcCtD
Methazolamide—Dermatitis—Niacin—atherosclerosis	0.000596	0.00317	CcSEcCtD
Methazolamide—Headache—Niacin—atherosclerosis	0.000593	0.00316	CcSEcCtD
Methazolamide—Vomiting—Pravastatin—atherosclerosis	0.000593	0.00315	CcSEcCtD
Methazolamide—Rash—Pravastatin—atherosclerosis	0.000588	0.00313	CcSEcCtD
Methazolamide—Dermatitis—Pravastatin—atherosclerosis	0.000587	0.00312	CcSEcCtD
Methazolamide—Headache—Pravastatin—atherosclerosis	0.000584	0.00311	CcSEcCtD
Methazolamide—Nausea—Niacin—atherosclerosis	0.000562	0.00299	CcSEcCtD
Methazolamide—Nausea—Pravastatin—atherosclerosis	0.000554	0.00295	CcSEcCtD
Methazolamide—CYP2E1—Metabolism—BGN—atherosclerosis	2.24e-05	0.000292	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—APOA5—atherosclerosis	2.22e-05	0.000289	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—FABP4—atherosclerosis	2.22e-05	0.000289	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—LCAT—atherosclerosis	2.22e-05	0.000289	CbGpPWpGaD
Methazolamide—CA9—Metabolism—INS—atherosclerosis	2.21e-05	0.000289	CbGpPWpGaD
Methazolamide—CA1—Metabolism—NOS3—atherosclerosis	2.21e-05	0.000288	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	2.2e-05	0.000287	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PTGS2—atherosclerosis	2.2e-05	0.000287	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—APOA4—atherosclerosis	2.17e-05	0.000284	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ABCG1—atherosclerosis	2.17e-05	0.000283	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ABCG1—atherosclerosis	2.15e-05	0.00028	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CYP7A1—atherosclerosis	2.14e-05	0.000279	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PLA2G1B—atherosclerosis	2.14e-05	0.000279	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PTGS2—atherosclerosis	2.11e-05	0.000275	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PLTP—atherosclerosis	2.07e-05	0.00027	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ALOX5—atherosclerosis	2.06e-05	0.000269	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—FABP4—atherosclerosis	2.04e-05	0.000266	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—LCAT—atherosclerosis	2.04e-05	0.000266	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	2.04e-05	0.000266	CbGpPWpGaD
Methazolamide—CA9—Metabolism—ALB—atherosclerosis	2.03e-05	0.000265	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PTGS2—atherosclerosis	2.02e-05	0.000264	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—FABP4—atherosclerosis	2.02e-05	0.000263	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—LCAT—atherosclerosis	2.02e-05	0.000263	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—APOA4—atherosclerosis	2e-05	0.000261	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—APOA4—atherosclerosis	1.98e-05	0.000259	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CYP27A1—atherosclerosis	1.97e-05	0.000258	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CYP7A1—atherosclerosis	1.97e-05	0.000256	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CYP7A1—atherosclerosis	1.95e-05	0.000254	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	1.94e-05	0.000254	CbGpPWpGaD
Methazolamide—CA9—Metabolism—NOS3—atherosclerosis	1.94e-05	0.000253	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	1.9e-05	0.000247	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ALOX15—atherosclerosis	1.87e-05	0.000244	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ALOX5AP—atherosclerosis	1.87e-05	0.000244	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PLA2G2A—atherosclerosis	1.87e-05	0.000244	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—APOA2—atherosclerosis	1.87e-05	0.000244	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	1.86e-05	0.000242	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—NAMPT—atherosclerosis	1.85e-05	0.000241	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ABCG5—atherosclerosis	1.85e-05	0.000241	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	1.85e-05	0.000241	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—LIPC—atherosclerosis	1.84e-05	0.00024	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—APOC3—atherosclerosis	1.83e-05	0.000238	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—LDLR—atherosclerosis	1.82e-05	0.000237	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CYP27A1—atherosclerosis	1.82e-05	0.000237	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CYP27A1—atherosclerosis	1.8e-05	0.000235	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ABCG8—atherosclerosis	1.79e-05	0.000234	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—LTA4H—atherosclerosis	1.79e-05	0.000234	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—LPA—atherosclerosis	1.79e-05	0.000233	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PTGS2—atherosclerosis	1.78e-05	0.000232	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CETP—atherosclerosis	1.77e-05	0.000231	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	1.77e-05	0.000231	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—BGN—atherosclerosis	1.73e-05	0.000226	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	1.73e-05	0.000226	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	1.72e-05	0.000225	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ALOX15—atherosclerosis	1.72e-05	0.000225	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	1.72e-05	0.000225	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—APOA2—atherosclerosis	1.72e-05	0.000225	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.72e-05	0.000224	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—APOA5—atherosclerosis	1.71e-05	0.000223	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ALOX15—atherosclerosis	1.71e-05	0.000223	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PLA2G2A—atherosclerosis	1.71e-05	0.000223	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—APOA2—atherosclerosis	1.71e-05	0.000223	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ALOX5AP—atherosclerosis	1.71e-05	0.000223	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ABCG5—atherosclerosis	1.7e-05	0.000222	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—SCARB1—atherosclerosis	1.7e-05	0.000222	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ABCG5—atherosclerosis	1.69e-05	0.00022	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	1.68e-05	0.00022	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.66e-05	0.000217	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PLA2G1B—atherosclerosis	1.65e-05	0.000215	CbGpPWpGaD
Methazolamide—CA14—Metabolism—AKT1—atherosclerosis	1.64e-05	0.000214	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—LPA—atherosclerosis	1.64e-05	0.000214	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.63e-05	0.000213	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—LPA—atherosclerosis	1.63e-05	0.000212	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.61e-05	0.000211	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.61e-05	0.00021	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—HMGCR—atherosclerosis	1.6e-05	0.000209	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—AKT1—atherosclerosis	1.6e-05	0.000209	CbGpPWpGaD
Methazolamide—CA6—Metabolism—AKT1—atherosclerosis	1.6e-05	0.000209	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ALOX5—atherosclerosis	1.59e-05	0.000208	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—BGN—atherosclerosis	1.59e-05	0.000207	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—BGN—atherosclerosis	1.58e-05	0.000206	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—APOA5—atherosclerosis	1.57e-05	0.000205	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.57e-05	0.000204	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—APOA5—atherosclerosis	1.56e-05	0.000204	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.52e-05	0.000198	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	1.52e-05	0.000198	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	1.5e-05	0.000196	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—AKT1—atherosclerosis	1.5e-05	0.000195	CbGpPWpGaD
Methazolamide—CA7—Metabolism—AKT1—atherosclerosis	1.5e-05	0.000195	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.49e-05	0.000194	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.47e-05	0.000192	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.47e-05	0.000192	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.47e-05	0.000192	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ALOX5—atherosclerosis	1.46e-05	0.000191	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ALOX5—atherosclerosis	1.45e-05	0.000189	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ABCA1—atherosclerosis	1.43e-05	0.000187	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—NAMPT—atherosclerosis	1.43e-05	0.000186	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.42e-05	0.000185	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—LIPC—atherosclerosis	1.42e-05	0.000185	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.42e-05	0.000185	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—APOC3—atherosclerosis	1.41e-05	0.000184	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—LDLR—atherosclerosis	1.4e-05	0.000183	CbGpPWpGaD
Methazolamide—CA12—Metabolism—AKT1—atherosclerosis	1.39e-05	0.000181	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CETP—atherosclerosis	1.37e-05	0.000179	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.34e-05	0.000175	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—FABP4—atherosclerosis	1.33e-05	0.000174	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—LCAT—atherosclerosis	1.33e-05	0.000174	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—NAMPT—atherosclerosis	1.31e-05	0.000171	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—SCARB1—atherosclerosis	1.31e-05	0.000171	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—APOA4—atherosclerosis	1.31e-05	0.000171	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—LIPC—atherosclerosis	1.31e-05	0.00017	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—NAMPT—atherosclerosis	1.3e-05	0.00017	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—APOC3—atherosclerosis	1.3e-05	0.000169	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.29e-05	0.000169	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—LIPC—atherosclerosis	1.29e-05	0.000169	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—LDLR—atherosclerosis	1.29e-05	0.000168	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—APOC3—atherosclerosis	1.29e-05	0.000168	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1.28e-05	0.000168	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—LDLR—atherosclerosis	1.28e-05	0.000167	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.28e-05	0.000166	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CETP—atherosclerosis	1.26e-05	0.000164	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CETP—atherosclerosis	1.25e-05	0.000163	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—HMGCR—atherosclerosis	1.24e-05	0.000161	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—HMOX1—atherosclerosis	1.23e-05	0.00016	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—SCARB1—atherosclerosis	1.21e-05	0.000157	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—SCARB1—atherosclerosis	1.2e-05	0.000156	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CYP27A1—atherosclerosis	1.19e-05	0.000155	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—APOB—atherosclerosis	1.18e-05	0.000153	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.16e-05	0.000152	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GSTM1—atherosclerosis	1.14e-05	0.000149	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—HMGCR—atherosclerosis	1.14e-05	0.000149	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—HMGCR—atherosclerosis	1.13e-05	0.000147	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—APOA2—atherosclerosis	1.13e-05	0.000147	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	1.13e-05	0.000147	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	1.13e-05	0.000147	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ALOX15—atherosclerosis	1.13e-05	0.000147	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—LPL—atherosclerosis	1.12e-05	0.000146	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.12e-05	0.000146	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ABCG5—atherosclerosis	1.11e-05	0.000145	CbGpPWpGaD
Methazolamide—CA4—Metabolism—AKT1—atherosclerosis	1.1e-05	0.000144	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ABCA1—atherosclerosis	1.1e-05	0.000144	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GPX1—atherosclerosis	1.09e-05	0.000143	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—LPA—atherosclerosis	1.07e-05	0.00014	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CD36—atherosclerosis	1.07e-05	0.000139	CbGpPWpGaD
Methazolamide—CA2—Metabolism—AKT1—atherosclerosis	1.06e-05	0.000138	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—BGN—atherosclerosis	1.04e-05	0.000136	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—APOA5—atherosclerosis	1.03e-05	0.000134	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.02e-05	0.000133	CbGpPWpGaD
Methazolamide—CA1—Metabolism—AKT1—atherosclerosis	1.02e-05	0.000132	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ABCA1—atherosclerosis	1.01e-05	0.000132	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—MTHFR—atherosclerosis	1.01e-05	0.000132	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ABCA1—atherosclerosis	1.01e-05	0.000131	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PPARA—atherosclerosis	9.91e-06	0.000129	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	9.91e-06	0.000129	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—AGT—atherosclerosis	9.6e-06	0.000125	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ALOX5—atherosclerosis	9.57e-06	0.000125	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—HMOX1—atherosclerosis	9.47e-06	0.000123	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—APOE—atherosclerosis	9.41e-06	0.000123	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CAV1—atherosclerosis	9.32e-06	0.000122	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—APOA1—atherosclerosis	9.3e-06	0.000121	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—APOB—atherosclerosis	9.07e-06	0.000118	CbGpPWpGaD
Methazolamide—CA9—Metabolism—AKT1—atherosclerosis	8.93e-06	0.000116	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GSTM1—atherosclerosis	8.82e-06	0.000115	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—HMOX1—atherosclerosis	8.71e-06	0.000114	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—LPL—atherosclerosis	8.66e-06	0.000113	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—HMOX1—atherosclerosis	8.63e-06	0.000113	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—NAMPT—atherosclerosis	8.59e-06	0.000112	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—LIPC—atherosclerosis	8.53e-06	0.000111	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PIK3CG—atherosclerosis	8.49e-06	0.000111	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—APOC3—atherosclerosis	8.48e-06	0.000111	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GPX1—atherosclerosis	8.45e-06	0.00011	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—LDLR—atherosclerosis	8.43e-06	0.00011	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—APOB—atherosclerosis	8.34e-06	0.000109	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—APOB—atherosclerosis	8.27e-06	0.000108	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CETP—atherosclerosis	8.23e-06	0.000107	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CD36—atherosclerosis	8.23e-06	0.000107	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PPARG—atherosclerosis	8.19e-06	0.000107	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GSTM1—atherosclerosis	8.11e-06	0.000106	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GSTM1—atherosclerosis	8.04e-06	0.000105	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—INS—atherosclerosis	8.04e-06	0.000105	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—LPL—atherosclerosis	7.96e-06	0.000104	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—LPL—atherosclerosis	7.89e-06	0.000103	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—SCARB1—atherosclerosis	7.88e-06	0.000103	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—MTHFR—atherosclerosis	7.8e-06	0.000102	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GPX1—atherosclerosis	7.77e-06	0.000101	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GPX1—atherosclerosis	7.7e-06	0.0001	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PPARA—atherosclerosis	7.65e-06	9.98e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CD36—atherosclerosis	7.57e-06	9.87e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CD36—atherosclerosis	7.5e-06	9.78e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—HMGCR—atherosclerosis	7.44e-06	9.71e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—AGT—atherosclerosis	7.41e-06	9.66e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ALB—atherosclerosis	7.37e-06	9.61e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—APOE—atherosclerosis	7.26e-06	9.47e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CAV1—atherosclerosis	7.19e-06	9.38e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—APOA1—atherosclerosis	7.17e-06	9.36e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—MTHFR—atherosclerosis	7.17e-06	9.35e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—MTHFR—atherosclerosis	7.11e-06	9.27e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—NOS3—atherosclerosis	7.05e-06	9.19e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PPARA—atherosclerosis	7.03e-06	9.17e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PPARA—atherosclerosis	6.97e-06	9.1e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—AGT—atherosclerosis	6.81e-06	8.89e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—AGT—atherosclerosis	6.75e-06	8.81e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—APOE—atherosclerosis	6.68e-06	8.71e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ABCA1—atherosclerosis	6.64e-06	8.65e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—APOE—atherosclerosis	6.62e-06	8.63e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CAV1—atherosclerosis	6.61e-06	8.63e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—APOA1—atherosclerosis	6.6e-06	8.61e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CAV1—atherosclerosis	6.56e-06	8.55e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PIK3CG—atherosclerosis	6.55e-06	8.54e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—APOA1—atherosclerosis	6.54e-06	8.53e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PTGS2—atherosclerosis	6.45e-06	8.41e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PPARG—atherosclerosis	6.32e-06	8.24e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—INS—atherosclerosis	6.2e-06	8.09e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PIK3CG—atherosclerosis	6.02e-06	7.86e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PIK3CG—atherosclerosis	5.97e-06	7.79e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PPARG—atherosclerosis	5.81e-06	7.58e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PPARG—atherosclerosis	5.76e-06	7.52e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—INS—atherosclerosis	5.7e-06	7.44e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—HMOX1—atherosclerosis	5.69e-06	7.42e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ALB—atherosclerosis	5.68e-06	7.41e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—INS—atherosclerosis	5.65e-06	7.37e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—APOB—atherosclerosis	5.45e-06	7.11e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—NOS3—atherosclerosis	5.44e-06	7.09e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GSTM1—atherosclerosis	5.3e-06	6.92e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ALB—atherosclerosis	5.23e-06	6.82e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—LPL—atherosclerosis	5.21e-06	6.79e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ALB—atherosclerosis	5.18e-06	6.76e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GPX1—atherosclerosis	5.08e-06	6.63e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—NOS3—atherosclerosis	5e-06	6.52e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PTGS2—atherosclerosis	4.97e-06	6.49e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—NOS3—atherosclerosis	4.96e-06	6.47e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CD36—atherosclerosis	4.95e-06	6.45e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—MTHFR—atherosclerosis	4.69e-06	6.11e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PPARA—atherosclerosis	4.6e-06	6e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PTGS2—atherosclerosis	4.57e-06	5.97e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PTGS2—atherosclerosis	4.53e-06	5.91e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—AGT—atherosclerosis	4.45e-06	5.81e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—APOE—atherosclerosis	4.36e-06	5.69e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CAV1—atherosclerosis	4.32e-06	5.64e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—APOA1—atherosclerosis	4.31e-06	5.63e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.94e-06	5.14e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PPARG—atherosclerosis	3.8e-06	4.96e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—INS—atherosclerosis	3.73e-06	4.86e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ALB—atherosclerosis	3.42e-06	4.46e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—NOS3—atherosclerosis	3.27e-06	4.26e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—AKT1—atherosclerosis	3.24e-06	4.23e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.99e-06	3.9e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—AKT1—atherosclerosis	2.5e-06	3.26e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—AKT1—atherosclerosis	2.3e-06	3e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—AKT1—atherosclerosis	2.28e-06	2.97e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—AKT1—atherosclerosis	1.5e-06	1.96e-05	CbGpPWpGaD
